BioCryst director receives RSU and option grants

BIOCRYST PHARMACEUTICALS INC director equity awards: Director Steven Frank received a grant of 15,294 shares of Common Stock as Restricted Stock Units under the company’s Non-Employee Director Compensation Policy.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director equity awards: Director Steven Frank received a grant of 15,294 shares of Common Stock as Restricted Stock Units under the company’s Non-Employee Director Compensation Policy. These RSUs will vest on the first anniversary of the June 11, 2026 grant date.

Frank also received an automatic non-employee director stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable from June 11, 2027 and expiring June 11, 2036. After these awards, he directly holds 35,459 shares of Common Stock.

Insider Trade Summary

Grant/Award: 48,834 shares

Grant/Award 2 txns

Insider Frank Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	$0.00
Grant/Award	Common Stock	15,294	$0.00	$0.00

Holdings After Transaction: Automatic Stock Option Grant — 33,540 contracts (Direct); Common Stock — 35,459 shares (Direct)

Footnotes (2)

1. F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2. F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

RSU grant: 15,294 shares Option grant size: 33,540 shares Option exercise price: $8.50 per share +3 more

6 metrics

RSU grant 15,294 shares Automatic non-employee director RSU grant on June 11, 2026

Option grant size 33,540 shares Automatic Stock Option Grant on June 11, 2026

Option exercise price $8.50 per share Exercise price for Automatic Stock Option Grant

Shares held after transaction 35,459 shares Common Stock directly owned after June 11, 2026 awards

Option exercisability date June 11, 2027 Date options become exercisable

Option expiration date June 11, 2036 Expiry of Automatic Stock Option Grant

Key Terms

Restricted Stock Units, Non-Employee Director Compensation Policy, Automatic Stock Option Grant, stock options, +1 more

5 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended"

Automatic Stock Option Grant financial

"Automatic Stock Option Grant"

stock options financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Common Stock financial

"underlying security title: Common Stock, underlying security shares: 33540.0000"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BIOCRYST (BCRX) report for Steven Frank?

Steven Frank received equity awards, not open-market trades. He was granted 15,294 Restricted Stock Units and stock options on 33,540 shares on June 11, 2026, as part of BIOCRYST’s Non-Employee Director Compensation Policy.

How many BIOCRYST (BCRX) RSUs were granted to director Steven Frank?

Steven Frank received 15,294 Restricted Stock Units. These RSUs were granted automatically under BIOCRYST’s Non-Employee Director Compensation Policy on June 11, 2026 and are scheduled to vest on the first anniversary of the grant date.

What are the terms of Steven Frank’s BIOCRYST (BCRX) stock options?

Frank was granted options on 33,540 shares at $8.50. The Automatic Stock Option Grant has a $8.50 per share exercise price, becomes exercisable on June 11, 2027, and expires on June 11, 2036, covering BIOCRYST Common Stock.

Do the reported BIOCRYST (BCRX) Form 4 transactions involve stock sales?

No, the transactions reflect awards, not sales. Both entries are coded “A” for grant or award acquisitions, covering Restricted Stock Units and stock options granted under the Non-Employee Director Compensation Policy, with no open-market buying or selling reported.

How many BIOCRYST (BCRX) shares does Steven Frank hold after these awards?

Frank directly holds 35,459 BIOCRYST Common shares after the grant. This figure reflects his post-transaction ownership following receipt of 15,294 Restricted Stock Units awarded on June 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frank Steven

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	35,459	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)